Body height; Bone development; Buserelin; Puberty; Testosterone
Abstract :
[en] One boy and 13 girls with central precocious puberty were treated for 1 year using Buserelin, a GnRH analogue, given intranasally (0.3mg, four times a day). After 1, 3 and 12 months of therapy, the gonadotropin responses to GnRH were abolished in all the patients whereas mean basal serum concentrations of luteinizing hormone (LH) remained similar to those of pubertal controls. During Buserelin treatment, genital development in the boy and breast development in the girls showed no further progress or some regression. In the boy, serum testosterone levels returned to prepubertal values. In the girls, serum oestradiol levels were variable and, in four of them, vaginal smears showed the persistence of a slight oestrogenic effect during therapy. Pelvic ultrasonography did not show any significant variation in ovarian and uterine lengths. Among the 14 patients, 3 had some progression of pubic hair development, irrespective of serum dehydroepiandrosterone sulphate (DHEAS) levels. In eight patients previously treated with cyproterone, elevated prolactin levels were observed before and during the first month of Buserelin administration. During treatment, mean height velocity was markedly reduced from 11.6 to 6.1 cm/year and mean bone age velocity (+/- 1SD) was 0.85 +/- 0.38 year/year. After 1 year of treatment, the differences in predicted adult height ranged between -0.74 and + 1.04 SDS (standard deviation score). These differences were inversely related (r = -0.72) to the prognosis of adult height calculated before treatment. We conclude that, in central precocious puberty, intranasal administration of Buserelin 1.2 mg/day, may arrest sexual development and reduce height velocity and bone maturation. Improvement of adult height prognosis may occur, especially when it was markedly impaired before treatment.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Bourguignon, Jean-Pierre ; Université de Liège - ULiège > Département des sciences cliniques > Pédiatrie
Van Vliet, G.
Vandeweghe, M.
Malvaux, P.
Vanderschueren-Lodeweyckx, M.
Craen, M.
Du Caju, M. V. L.
Ernould, Christian ; Université de Liège - ULiège > Département des sciences cliniques > Pédiatrie
Language :
English
Title :
Treatment of Central Precocious Puberty with an Intranasal Analogue of GnRH (Buserelin)
Bayley N., Pinneau S.R. (1952) Tables predicting adult height from skeletal age: Revised for use with Greulich-Pyle hand standards. J Pediatr 40:423-441.
Belchetz P.E., Plant T.M., Nakai Y., Keogh E.J., Knobil E. (1978) Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin releasing hormone. Science 202:631-633.
Bierich J.R. (1975) Sexual precocity. Clin Endocrinol Metab 4:107.
Boepple P.A., Mansfield M.J., Wierman M.E., Rudlin C.R., Bode H.H., Crigler J.F., Crawford J.D., Crowley W.F. (1986) Use of a potent, long-acting agonist of gonadotropin releasing hormone in the treatment of precocious puberty. Endocr Rev 7:24-33.
Bourguignon J.P., Burger H.G., Franchimont P. (1974) Radioimmunoassay of serum luteinizing hormone-releasing hormone (LH-RH) after intranasal administration and evaluation of the pituitary gonadotrophic response. Clin Endocrinol 3:437-440.
Bourguignon J.P., Vanderschueren-Lodeweyckx M., Malvaux P., Craen M., Du Caju M.V.L., Ernould C., Franchimont P. (1982) Hypopituitarism and idiopathic delayed puberty: a longitudinal study in an attempt to diagnose gonadotropin deficiency before puberty. J Clin Endocrinol Metab 54:733-744.
Bramley T.A., Menzies G.S., Baird D.T. (1985) Specific binding of gonadotropin releasing hormone and an agonist to human corpus luteum homogenates: characterization, properties and luteal phase levels. J Clin Endocrinol Metab 61:834-841.
Brauner R., Thibaud E., Bischof P., Sizonenko P.C., Rappaport R. (1985) Long-term results of GnRH analogue (Buserelin) treatment in girls with central precocious puberty. Acta Pediatr Scand 74:945-951.
Buckler J.M.H. (1984) Skeletal age changes in puberty. Arch Dis Child 59:115-119.
Clayton R.N., Huhtaniemi I.T. (1982) Absence of gonadotropin releasing hormone receptors in human gonadal tissue. Nature 299:56-59.
Crowley W.F., Comite F., Vale W., Rivier J., Loriaux D.L., Cutler G.B. (1981) Therapeutic use of pituitary desensitization with a long acting LHRH agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 52:370-372.
Crowley W.F., Filicori M., Spratt D.I., Santoro N.F. (1985) The physiology of gonadotropin releasing hormone (GnRH) secretion in men and women. Recent Prog Horm Res 41:473-531.
Evans R.M., Doelle G.C., Alexander A.N., Uderman H.D., Rabin D. (1984) Gonadotropin and steroid secretory patterns during chronic treatment with a luteinizing hormone-releasing hormone agonist analog in men. J Clin Endocrinol Metab 58:862-867.
Fonzo D., Angeli A., Sivieri R., Andriolo S., Frajria R., Cesera F. (1977) Hyperprolactinemia in girls with idiopathic precocious puberty under prolonged treatment with cyproterone acetate. J Clin Endocrinol Metab 45:164-168.
Graf K.J., Schmidt-Gollwitzer M., Koch U.J., Lorenz F., Hammerstein J. (1978) Hyperprolactinemia induced by cyproterone acetate in human subjects. J Endocrinol Invest 87:96.
Greulich W.W., Pyle S.I. Radiographic atlas of skeletal development of the hand and wrist, 2nd edn., Stanford University Press, Stanford; 1959.
Harris D.A., Van Vliet G., Egli C.A., Grumbach M.M., Kaplan S.L., Styne D.M., Vainsel M. (1985) Somatomedin C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist. J Clin Endocrinol Metab 61:152-159.
Heather J.D., Whitehead S.A. (1985) Changes in pituitary responsiveness to LH-releasing hormone after acute Buserelin treatment: a time-course and dose-dependent study. J Endocrinol 106:27-30.
Holland F.J., Fishman L., Costigan D.C., Luna L., Leeder S. (1986) Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog d-ser-(TBU)6-EA10 luteinizing hormone-releasing hormone (Buserelin) after subcutaneous and intranasal admidnistration in children with central precocious puberty. J Clin Endocrinol Metab 63:1065-1070.
Hsueh A.J.W., Jones P.B.C. (1981) Extra-pituitary actions of gonadotropin releasing hormone. Endocr Rev 2:437-452.
Kauli R., Pertzelan A., Prager-Lewin R., Grunebau M., Laron Z. (1976) Cyproterone acetate in treatment of precocious puberty. Arch Dis Child 51:202-208.
Kauli R., Pertzelan A., Ben Zeev Z., Prager-Lewin R., Kaufman H., Comaru Schally A.M., Schally A.V., Laron Z. (1984) Treatment of precocious puberty with LHRH analogue in combination with cyproterone acetate. Further experience. Clin Endocrinol 20:377-387.
Knobil E. (1980) The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 36:53-88.
Lee P.A. (1981) Medroxyprogesterone therapy for sexual precocity in girls. Am J Dis Child 135:443-447.
Luder A.S., Holland F.J., Costigan D.C., Jenner, Wielgosz G., Fazekas A.T.A. (1984) Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 58:966-972.
Mann D.R., Gould K.H., Collins D.C. (1984) Influence of continous gonadotropin-releasing hormone (GnRH) agonist treatment on luteinizing hormone and testosterone secretion, the response to GnRH, and the testicular response to human chorionic gonadotropin in male rhesus monkeys. J Clin Endocrinol Metab 58:262-267.
Mansfield M.J., Beardsworth D.E., Loughlin J.S., Crawford J.D., Bode H.H., Rivier J., Vale W., Kushner D.C., Crigler J.F., Crowley W.F. (1983) Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation. N Engl J Med 309:1286-1290.
Pieper D.R., Richards J.S., Marshall J.C. (1981) Ovarian gonadotropin releasing hormone (GnRH) receptors: characterization, distribution and induction by GnRH. Endocrinology 108:1148-1155.
Reznik Y., Winiger B.P., Aubert M.L., Sizonenko P.C. (1984) Pharmacodynamics of [Desgly10, d-Ser (t-Bu)6]-GnRH-EA in 6 normal volunteers and in 2 girls with precocious puberty. Pediatr Res , abstr; 182:1210.
Rudlin C.R., Mansfield M.J., Crigler J.F., Karol K.A., Crawford J.D., Boepple P.A., Crowley W.F. (1985) Decrease in growth hormone and somatomedin C during LHRH agonist treatment of central precocious puberty. Pediatric Research , abstr; 19:633.
Roger M., Chaussain J.L., Berlier P., Bost M., Canlorbe P., Colle M., Francois R., Garandeau P., Lahlou N., Morel Y., Schally A.V. (1986) Long-term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-TRP6-luteinizing hormone-releasing hormone microcapsules. J Clin Endocrinol Metab 62:670-677.
Sandow J. (1983) Clinical applications of LHRH and its analogues. Clin Endocrinol 18:571-592.
Sandow J., Rechenberg W.V., Baeder C., Engelbart K. (1980) Antifertility effects of an LHRH analogue in male rats and dogs. Int J Fertil 25:213-221.
Schaison G., Brailly S., Vuagnat P., Bouchard P., Milgrom E. (1984) Absence of direct inhibitory effect of the GnRH d-Ser (TBU)6, Desgly-NH210 GnRH ethylamide (Buserelin) on testicular steroidogenesis in men. J Clin Endocrinol Metab 58:885-890.
Schurmeyer T.H., Knuth U.A., Freischem C.W., Sandow J., Bint Akhtar F., Nieschlag E. (1984) Suppression of pituitary and testicular function in normal men by constant gonadotropin-releasing hormone agonist infusion. The Journal of Clinical Endocrinology & Metabolism 59:19-24.
Smith R., Donald R.A., Espiner E.A., Stronach S. (1979) The effects of prolonged administration of d-SER (TBU)6-LHRH-EA10 (HOE 766) in subjects with hypogonadotropic hypogonadism. Clin Endocrinol 11:553-559.
Stanhope R., Ada J., Brook C.G.D. (1985) The treatment of central precocious puberty using an intranasal LHRH analogue (Buserelin). Clin Endocrinol 26:795-806.
Styne D.M., Harris D.A., Egli C.A., Conte F.A., Kaplan S.L., Rivier J., Vale W., Grumbach M.M. (1985) Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography and the hypothalamic-pituitary-gonadal axis. J Clin Endocrinol Metab 61:142-151.
Tanner J.M. Growth at adolescence, 2nd ed., Blackwell, Oxford; 1962.
Tanner J.M., Whitehouse R.H., Takaishi M. (1965) Standards from birth to maturity for height, weight, height velocity and weight velocity: British children 1965. Arch Dis Child 41:454-471.
Tanner J.M., Goldstein H., Whitehouse R.H. (1970) Standards for children’s height at ages 2–9 years allowing for height of parents. Arch Dis Child 45:755-762.
Tanner J.M., Whitehouse R.H., Marshall W.A., Healy M.J.R., Goldstein H. Assessment of skeletal maturity and prediction of adult height, Academic Press, London New York; 1975.
Tanner J.M., Landt K.W., Cameron N., Carter B.S., Patel J. (1983) Prediction of adult height from height and bone age in childhood. A new system of equations (TW mark II) based on a sample including very tall and very short children. Arch Dis Child 58:767-776.
Werder E.A., Murset G., Zachmann M., Brook C.G.D., Prader A. (1974) Treatment of precocious puberty with cyproterone acetate. Pediatr Res 8:248-255.
Yen S.S.C. (1983) Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs. Fertil Steril 39:257-266.
Zachmann M., Sobradillo B., Frank M., Frisch H., Prader A. (1978) Bayley-Pinneau, Roche-Wainer-Thissen, and Tanner height predictions in normal children and in patients with various pathologic conditions. J Pediatr 93:749-755.